SCHEMBL464740

SCHEMBL464740

Cc1cc(C)on1.NS(=O)(=O)c1cccc2c1OCO2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.36
PTGS1 P23219 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
TP53 P04637 2/20 0.35
POLB P06746 2/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
EPHB4 P54760 1/20 0.35
DRD2 P14416 2/20 0.34
HTR2A P28223 2/20 0.34
DRD3 P35462 2/20 0.34
CHRM1 P11229 1/20 0.34
MAOB P27338 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
CA12 O43570 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL464734 0.82 ABCG2 (0.41) PTGS2PTGS1TSHREPHB4CHRM1
SCHEMBL464814 0.78 CA12 (0.40) PTGS2PTGS1SMN1; SMN2TP53POLB
SCHEMBL464723 0.71 MGAM (0.37) PTGS2PTGS1SMN1; SMN2POLBEPHB4
SCHEMBL464724 0.71 ALDH1A1 (0.39) PTGS2PTGS1POLBEPHB4DRD2
SCHEMBL10664550 0.70 ACLY (0.44) PTGS2PTGS1SMN1; SMN2CA12CA2
SCHEMBL464731 0.70 MGAM (0.37) PTGS2PTGS1POLBEPHB4CHRM1
SCHEMBL464729 0.69 PTGS1 (0.43) PTGS2PTGS1SMN1; SMN2TP53POLB
SCHEMBL464730 0.68 EED (0.39) PTGS2PTGS1HTR2ACA2MGAM
SCHEMBL464779 0.67 GSK3B (0.42) PTGS2PTGS1POLBTSHRCHRM1
SCHEMBL4749803 0.67 MAOB (0.43) SMN1; SMN2TP53POLBTSHRCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
EP-1686113-B1 Inhibitors of aspartyl protease VERTEX PHARMA (US) 2011-11-23 EP disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1686113-A1 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-08-02 EP disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed
EP-1194404-A1 INHIBITORS OF ASPARTYL PROTEASE Vertex Pharmaceuticals Incorporated (US) 2002-04-10 EP disclosed
WO-2000076961-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 PTGS2 1822/4885PTGS1 2228/4885SMN1; SMN2 2568/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 PTGS2 1822/4885PTGS1 2228/4885SMN1; SMN2 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.